Inclusion Criteria:

- Adult patients, >=18 years of age

- Metastatic colorectal cancer and disease progression

- Previously treated with first-line chemotherapy plus Avastin

- ECOG <=2.

Exclusion Criteria:

- Diagnosis of progression of disease more than 3 months after last Avastin
administration

- First-line patients with progression-free survival in first-line of <3 months

- Patients receiving less than 3 consecutive months of Avastin in first-line therapy

- Past or current history (within the last 2 years prior to treatment start) of other
malignancies, except for curatively treated basal and squamous cell cancer of the
skin or in situ cancer of the cervix

- Clinically significant cardiovascular disease within 6 months prior to start of study
treatment

- Known CNS disease, except for treated CNS metastases as defined by protocol